Lactose (India) Reports Strong Financial Metrics Amidst Cash Flow Challenges

Lactose (India), a microcap player in the Pharmaceuticals and Biotechnology sector, has recently undergone a financial trend adjustment reflecting its performance in the quarter ending September 2025. The company reported notable financial metrics, with operating profit to interest reaching a robust 5.05 times, and net sales hitting a record Rs 41.18 crore. Additionally, key indicators such as PBDIT and PBT less other income also marked their highest levels at Rs 5.25 crore and Rs 2.77 crore, respectively. The profit after tax (PAT) for the quarter stood at Rs 2.16 crore, translating to an earnings per share (EPS) of Rs 1.72.
However, challenges remain, particularly in operating cash flow, which recorded a low of Rs -0.29 crore. Furthermore, the PAT for the nine-month period has seen a decline of 35.82%, indicating some underlying issues that the company must address.

In terms of market performance, Lactose (India) has faced significant challenges compared to the Sensex. Over the past year, the stock has declined by 37.71%, while the Sensex has gained 8.74%. Despite a strong performance in certain financial metrics, the overall return on investment has been less favorable, particularly in the short term.